Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Autoimmune Disorders

Free Subscription Articles published in Lancet Retrieve available abstracts of 48 articles: HTML format

Single Articles

February 2026
1. GROARKE EM, Turturice B, Patel BA, Quinn KA, et al
   VEXAS syndrome: a comprehensive review of pathogenesis, clinical spectrum, and therapeutic strategies.
   Lancet. 2026;407:637-648.
   PubMed     Abstract available
   
   
   January 2026
2. ABIZAID A, Mehran R, Oliva A, Chamie D, et al
   Abluminus DES+ sirolimus-eluting stent versus everolimus-eluting stent in patients with diabetes and coronary artery disease (ABILITY Diabetes Global): results from a multicentre, randomised controlled trial.
   Lancet. 2026 Jan 8:S0140-6736(25)02157-9. doi: 10.1016/S0140-6736(25)02157.
   PubMed     Abstract available
   
   
   November 2025
3. FISHER BA
   Nipocalimab for Sjogren's disease-the importance of autoantibodies.
   Lancet. 2025;406:2397-2398.
   PubMed    
   
   
   
4. GAO J, Li M, Sun M, Yu Y, et al
   Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China.
   Lancet. 2025 Nov 12:S0140-6736(25)01671-X. doi: 10.1016/S0140-6736(25)01671.
   PubMed     Abstract available
   
   
   
5. ZIEGLER AG, Achenbach P, Weiss A, Berner R, et al
   Efficacy of once-daily, high-dose, oral insulin immunotherapy in children genetically at risk for type 1 diabetes (POInT): a European, randomised, placebo-controlled, primary prevention trial.
   Lancet. 2025 Nov 11:S0140-6736(25)01726-X. doi: 10.1016/S0140-6736(25)01726.
   PubMed     Abstract available
   
   
   October 2025
6. CACOUB P, Vieira M, Langford CA, Tazi Mezalek Z, et al
   Large-vessel vasculitis.
   Lancet. 2025;406:2017-2032.
   PubMed     Abstract available
   
   
   
7. FILIPPI M, Rocca MA
   MS-STAT2: lessons from negative trials in multiple sclerosis.
   Lancet. 2025 Oct 1:S0140-6736(25)01673-3. doi: 10.1016/S0140-6736(25)01673.
   PubMed    
   
   
   
8. CHATAWAY J, Williams T, Blackstone J, John N, et al
   Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial.
   Lancet. 2025 Oct 1:S0140-6736(25)01039-6. doi: 10.1016/S0140-6736(25)01039.
   PubMed     Abstract available
   
   
   September 2025
9. ZIEGLER AG, Cengiz E, Kay TWH
   The future of type 1 diabetes therapy.
   Lancet. 2025 Sep 19:S0140-6736(25)01438-2. doi: 10.1016/S0140-6736(25)01438.
   PubMed     Abstract available
   
   
   
10. MATHIEU C, Wych J, Hendriks AEJ, Van Ryckeghem L, et al
    Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial.
    Lancet. 2025 Sep 18:S0140-6736(25)01674-5. doi: 10.1016/S0140-6736(25)01674.
    PubMed     Abstract available
    
    
    March 2025
11. BANERJEE SS, Sahai S, Chate GP
    Guillain-Barre syndrome outbreak in Pune: a health emergency.
    Lancet. 2025 Mar 21:S0140-6736(25)00414-3. doi: 10.1016/S0140-6736(25)00414.
    PubMed    
    
    
    
12. LATEEF S
    India faces major Guillain-Barre syndrome epidemic.
    Lancet. 2025;405:769.
    PubMed    
    
    
    January 2025
13. ACHARYA NR, Ramanan AV, Coyne AB, Dudum KL, et al
    Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trial.
    Lancet. 2025;405:303-313.
    PubMed     Abstract available
    
    
    
14. BENHADOU F, Cogan E
    Targeting IFNbeta in dermatomyositis.
    Lancet. 2025;405:99-101.
    PubMed    
    
    
    
15. FIORENTINO D, Mangold AR, Werth VP, Christopher-Stine L, et al
    Efficacy, safety, and target engagement of dazukibart, an IFNbeta specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
    Lancet. 2025;405:137-146.
    PubMed     Abstract available
    
    
    November 2024
16. DE FREMONT GM, Lenfant T, Le Guern V, Costedoat-Chalumeau N, et al
    Therapies for systemic lupus erythematosus.
    Lancet. 2024;404:2163.
    PubMed    
    
    
    
17. MATUCHANSKY C
    Therapies for systemic lupus erythematosus.
    Lancet. 2024;404:2163.
    PubMed    
    
    
    
18. HOI A, Igel T, Mok CC, Arnaud L, et al
    Therapies for systemic lupus erythematosus - Authors' reply.
    Lancet. 2024;404:2163-2164.
    PubMed    
    
    
    
19. XU Q
    Therapies for systemic lupus erythematosus.
    Lancet. 2024;404:2162.
    PubMed    
    
    
    
20. PABST T, Maurer B
    Therapies for systemic lupus erythematosus.
    Lancet. 2024;404:2162.
    PubMed    
    
    
    
21. HAGEN M, Muller F, Wirsching A, Kharboutli S, et al
    Treatment of CNS systemic lupus erythematosus with CD19 CAR T cells.
    Lancet. 2024;404:2158-2160.
    PubMed    
    
    
    September 2024
22. LOVE KM, Brown SA
    The promise of once-weekly insulins for type 1 diabetes: update on progress.
    Lancet. 2024;404:1081-1083.
    PubMed    
    
    
    
23. BERGENSTAL RM, Weinstock RS, Mathieu C, Onishi Y, et al
    Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial.
    Lancet. 2024;404:1132-1142.
    PubMed     Abstract available
    
    
    August 2024
24. AL-SAMKARI H, B Bussel J, Miyakawa Y, Broome CM, et al
    Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial - Authors' reply.
    Lancet. 2024;404:434.
    PubMed    
    
    
    
25. JACOBS JW, Booth GS, Stephens LD, Tormey CA, et al
    Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial.
    Lancet. 2024;404:433.
    PubMed    
    
    
    
26. MA RW, Liu K, Xie J
    Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial.
    Lancet. 2024;404:433-434.
    PubMed    
    
    
    July 2024
27. SCHETT G, Mackensen A, Mougiakakos D
    CAR T-cell perspectives in lupus - Authors' reply.
    Lancet. 2024;404:336-337.
    PubMed    
    
    
    
28. GREMESE E, Bruno D, Ferraccioli G
    CAR T-cell perspectives in lupus.
    Lancet. 2024;404:336.
    PubMed    
    
    
    June 2024
29. LAFAYETTE R, Kristensen J, Stone A, Barratt J, et al
    Targeted release of budesonide in primary IgA nephropathy - Authors' reply.
    Lancet. 2024;403:2786.
    PubMed    
    
    
    
30. ZOU Y, Du X, Zou J
    Targeted release of budesonide in primary IgA nephropathy.
    Lancet. 2024;403:2785-2786.
    PubMed    
    
    
    
31. HU Y, Zhang Y
    Targeted release of budesonide in primary IgA nephropathy.
    Lancet. 2024;403:2785.
    PubMed    
    
    
    
32. SAKUMA I, Ishibashi R, Matsue K, Vatner DF, et al
    Primary adrenal insufficiency due to lymphomatoid granulomatosis in a 32-year-old man.
    Lancet. 2024;403:e33.
    PubMed    
    
    
    April 2024
33. HOI A, Igel T, Mok CC, Arnaud L, et al
    Systemic lupus erythematosus.
    Lancet. 2024 Apr 17:S0140-6736(24)00398-2. doi: 10.1016/S0140-6736(24)00398.
    PubMed     Abstract available
    
    
    
34. KRICKAU T, Naumann-Bartsch N, Aigner M, Kharboutli S, et al
    CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis.
    Lancet. 2024 Apr 17:S0140-6736(24)00424-0. doi: 10.1016/S0140-6736(24)00424.
    PubMed    
    
    
    February 2024
35. KRONBICHLER A, Bajema IM, Bruchfeld A, Mastroianni Kirsztajn G, et al
    Diagnosis and management of ANCA-associated vasculitis.
    Lancet. 2024;403:683-698.
    PubMed     Abstract available
    
    
    
36. VAN DER HELM-VAN MIL AHM
    Abatacept in individuals with autoantibody-positive arthralgia at risk for rheumatoid arthritis.
    Lancet. 2024 Feb 14:S0140-6736(24)00055-2. doi: 10.1016/S0140-6736(24)00055.
    PubMed    
    
    
    January 2024
37. WEST EE, Woodruff T, Fremeaux-Bacchi V, Kemper C, et al
    Complement in human disease: approved and up-and-coming therapeutics.
    Lancet. 2024;403:392-405.
    PubMed     Abstract available
    
    
    
38. CHAKER L, Cooper DS, Walsh JP, Peeters RP, et al
    Hyperthyroidism.
    Lancet. 2024 Jan 23:S0140-6736(23)02016-0. doi: 10.1016/S0140-6736(23)02016.
    PubMed     Abstract available
    
    
    November 2023
39. JAKIMOVSKI D, Bittner S, Zivadinov R, Morrow SA, et al
    Multiple sclerosis.
    Lancet. 2023 Nov 7:S0140-6736(23)01473-3. doi: 10.1016/S0140-6736(23)01473.
    PubMed     Abstract available
    
    
    
40. REICH HN, Barbour SJ
    PROTECTing the kidneys in IgA nephropathy.
    Lancet. 2023 Nov 3:S0140-6736(23)02418-2. doi: 10.1016/S0140-6736(23)02418.
    PubMed    
    
    
    
41. ROVIN BH, Barratt J, Heerspink HJL, Alpers CE, et al
    Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
    Lancet. 2023 Nov 2:S0140-6736(23)02302-4. doi: 10.1016/S0140-6736(23)02302.
    PubMed     Abstract available
    
    
    
42. SINGH M, Wambua S, Lee SI, Okoth K, et al
    Autoimmune diseases and adverse pregnancy outcomes: an umbrella review.
    Lancet. 2023;402 Suppl 1:S84.
    PubMed     Abstract available
    
    
    October 2023
43. ESPIGOL-FRIGOLE G, Dejaco C, Mackie SL, Salvarani C, et al
    Polymyalgia rheumatica.
    Lancet. 2023;402:1459-1472.
    PubMed     Abstract available
    
    
    
44. RUSSELL-JONES D, Babazono T, Cailleteau R, Engberg S, et al
    Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial.
    Lancet. 2023 Oct 17:S0140-6736(23)02179-7. doi: 10.1016/S0140-6736(23)02179.
    PubMed     Abstract available
    
    
    
45. SHAH AS, Wolf RM
    Weekly insulin: a paradigm shift in type 1 diabetes therapy.
    Lancet. 2023 Oct 17:S0140-6736(23)02227-4. doi: 10.1016/S0140-6736(23)02227.
    PubMed    
    
    
    September 2023
46. BROOME CM, McDonald V, Miyakawa Y, Carpenedo M, et al
    Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial.
    Lancet. 2023 Sep 28:S0140-6736(23)01460-5. doi: 10.1016/S0140-6736(23)01460.
    PubMed     Abstract available
    
    
    
47. MAHAMAD S, Arnold DM
    Inhibition of neonatal Fc receptor as a treatment for immune thrombocytopenia.
    Lancet. 2023 Sep 28:S0140-6736(23)01836-6. doi: 10.1016/S0140-6736(23)01836.
    PubMed    
    
    
    
48. SCHETT G, Mackensen A, Mougiakakos D
    CAR T-cell therapy in autoimmune diseases.
    Lancet. 2023 Sep 22:S0140-6736(23)01126-1. doi: 10.1016/S0140-6736(23)01126.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum